SG10201908019UA - MODIFIED-IgG ANTIBODIES THAT BIND TRANSFORMING GROWTH FACTOR-β1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY - Google Patents
MODIFIED-IgG ANTIBODIES THAT BIND TRANSFORMING GROWTH FACTOR-β1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITYInfo
- Publication number
- SG10201908019UA SG10201908019UA SG10201908019UA SG10201908019UA SG 10201908019U A SG10201908019U A SG 10201908019UA SG 10201908019U A SG10201908019U A SG 10201908019UA SG 10201908019U A SG10201908019U A SG 10201908019UA
- Authority
- SG
- Singapore
- Prior art keywords
- modified
- avidity
- high affinity
- specificity
- growth factor
- Prior art date
Links
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 title 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 title 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 229950005555 metelimumab Drugs 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000003375 selectivity assay Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000001131 transforming effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
MODIFIED -I g G ANTIBODIES THAT BI ND TRANSFORMING GROW TH FACTOR -β 1 WITH HIGH AFFINITY , AVIDITY AND SPECIF ICITY A modified IgG antibody binds and neutralizes TGFβ1 selectively and with high affinity 5 and avidity. The modified IgG antibody comprises four polypeptide chains and may comprise modifications to the elbow regions of the polypeptide chains. The modified IgG antibody may comprise the same VH and VL domains or CDR regions as metelimumab. The modified IgG antibody is useful in therapeutic and diagnostic applications. 10 [No Figure]
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562128149P | 2015-03-04 | 2015-03-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201908019UA true SG10201908019UA (en) | 2019-10-30 |
Family
ID=55524479
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201707109XA SG11201707109XA (en) | 2015-03-04 | 2016-03-03 | Modified-igg antibodies that bind transforming growth factor-beta1 with high affinity, avidity and specificity |
| SG10201908019U SG10201908019UA (en) | 2015-03-04 | 2016-03-03 | MODIFIED-IgG ANTIBODIES THAT BIND TRANSFORMING GROWTH FACTOR-β1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201707109XA SG11201707109XA (en) | 2015-03-04 | 2016-03-03 | Modified-igg antibodies that bind transforming growth factor-beta1 with high affinity, avidity and specificity |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11325970B2 (en) |
| EP (2) | EP4163299A1 (en) |
| JP (1) | JP6745275B2 (en) |
| KR (2) | KR20230116946A (en) |
| CN (1) | CN107787329B (en) |
| AR (1) | AR103840A1 (en) |
| AU (1) | AU2016226098B2 (en) |
| BR (1) | BR112017018678A2 (en) |
| CA (1) | CA2978439A1 (en) |
| DK (1) | DK3265487T3 (en) |
| ES (1) | ES2927297T3 (en) |
| HR (1) | HRP20221142T1 (en) |
| HU (1) | HUE059644T2 (en) |
| IL (1) | IL254239B2 (en) |
| LT (1) | LT3265487T (en) |
| MX (1) | MX2017011252A (en) |
| PL (1) | PL3265487T3 (en) |
| PT (1) | PT3265487T (en) |
| RS (1) | RS63589B1 (en) |
| RU (1) | RU2728858C2 (en) |
| SG (2) | SG11201707109XA (en) |
| SI (1) | SI3265487T1 (en) |
| TW (1) | TWI733661B (en) |
| WO (1) | WO2016141245A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI726870B (en) | 2015-03-04 | 2021-05-11 | 美商健臻公司 | scFv-Fc DIMERS THAT BIND TRANSFORMING GROWTH FACTOR-β1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY |
| TWI733661B (en) | 2015-03-04 | 2021-07-21 | 美商健臻公司 | MODIFIED-IgG ANTIBODIES THAT BIND TRANSFORMING GROWTH FACTOR-β1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY |
| CN109071646A (en) | 2016-03-11 | 2018-12-21 | 供石公司 | TGF β 1- binding domain-immunoglobulin and application thereof |
| WO2017189959A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| TWI787230B (en) | 2017-01-20 | 2022-12-21 | 法商賽諾菲公司 | Anti-tgf-beta antibodies and their use |
| US20210221849A1 (en) * | 2018-05-10 | 2021-07-22 | Mirabiologics Inc. | Artificial Protein Containing Antigen-Binding Region of Antibody and Being Fused With Physiologically Active Peptide |
| US20220119513A1 (en) * | 2020-06-08 | 2022-04-21 | Zoetis Services Llc | Anti-tgfb antibodies and therapeutic uses thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020099179A1 (en) | 1989-12-21 | 2002-07-25 | Linda K. Jolliffe | Cdr-grafted antibodies |
| US5616561A (en) | 1995-03-31 | 1997-04-01 | Regents Of The University Of California | TGF-β antagonists as mitigators of radiation-induced tissue damage |
| US6492497B1 (en) * | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
| EP1486560A3 (en) | 1999-04-30 | 2005-02-09 | Cambridge Antibody Technology LTD | Specific antibodies and antibody fragments for TGFBETA1 |
| US20060286105A1 (en) | 2003-04-30 | 2006-12-21 | Steven Ledbetter | Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency |
| RU2386638C2 (en) | 2004-03-31 | 2010-04-20 | Дженентек, Инк. | Humanised anti-tgf-beta-antibody |
| JP2008513542A (en) * | 2004-09-22 | 2008-05-01 | ジェンザイム・コーポレイション | Use of TGF-β antagonists to limit nephrotoxicity of immunosuppressants |
| US9284375B2 (en) | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| EP1874818B1 (en) | 2005-04-22 | 2011-04-13 | Eli Lilly And Company | Tgf beta 1 specific antibodies |
| AU2006330542B2 (en) | 2005-12-23 | 2012-05-24 | Eli Lilly And Company | TGF-beta binding compositions |
| WO2007109254A2 (en) | 2006-03-17 | 2007-09-27 | Biogen Idec Ma Inc. | Stabilized polypeptide compositions |
| KR20090013763A (en) | 2006-03-23 | 2009-02-05 | 기린 파마 가부시끼가이샤 | Agonistic antibody directed against human thrombopoietin receptor |
| EP3254696A1 (en) * | 2006-10-03 | 2017-12-13 | Genzyme Corporation | Use of tgf beta antagonists to treat infants at risk of developing bronchopulmonary dysplasia |
| CN102264390A (en) | 2008-07-02 | 2011-11-30 | 新兴产品开发西雅图有限公司 | IL6 immunotherapeutics |
| US9409950B2 (en) | 2010-12-23 | 2016-08-09 | Biogen Ma Inc. | Linker peptides and polypeptides comprising same |
| TWI743461B (en) * | 2011-03-28 | 2021-10-21 | 法商賽諾菲公司 | Dual variable region antibody-like binding proteins having cross-over binding region orientation |
| KR102051014B1 (en) * | 2011-06-03 | 2019-12-04 | 조마 테크놀로지 리미티드 | Antibodies specific for tgf-beta |
| US20140072581A1 (en) | 2012-07-23 | 2014-03-13 | Zymeworks Inc. | Immunoglobulin Constructs Comprising Selective Pairing of the Light and Heavy Chains |
| TWI664979B (en) | 2013-03-11 | 2019-07-11 | 健臻公司 | Engineered anti-tgf-beta antibodies and antigen-binding fragments |
| TWI726870B (en) | 2015-03-04 | 2021-05-11 | 美商健臻公司 | scFv-Fc DIMERS THAT BIND TRANSFORMING GROWTH FACTOR-β1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY |
| TWI733661B (en) | 2015-03-04 | 2021-07-21 | 美商健臻公司 | MODIFIED-IgG ANTIBODIES THAT BIND TRANSFORMING GROWTH FACTOR-β1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY |
-
2016
- 2016-03-02 TW TW105106247A patent/TWI733661B/en active
- 2016-03-03 SG SG11201707109XA patent/SG11201707109XA/en unknown
- 2016-03-03 EP EP22180865.2A patent/EP4163299A1/en active Pending
- 2016-03-03 AU AU2016226098A patent/AU2016226098B2/en active Active
- 2016-03-03 EP EP16709666.8A patent/EP3265487B1/en active Active
- 2016-03-03 JP JP2017546179A patent/JP6745275B2/en active Active
- 2016-03-03 KR KR1020237024971A patent/KR20230116946A/en active IP Right Grant
- 2016-03-03 RU RU2017134043A patent/RU2728858C2/en active
- 2016-03-03 DK DK16709666.8T patent/DK3265487T3/en active
- 2016-03-03 BR BR112017018678A patent/BR112017018678A2/en active Search and Examination
- 2016-03-03 PT PT167096668T patent/PT3265487T/en unknown
- 2016-03-03 MX MX2017011252A patent/MX2017011252A/en unknown
- 2016-03-03 CN CN201680025633.5A patent/CN107787329B/en active Active
- 2016-03-03 WO PCT/US2016/020780 patent/WO2016141245A1/en active Application Filing
- 2016-03-03 KR KR1020177027372A patent/KR102560072B1/en active IP Right Grant
- 2016-03-03 SG SG10201908019U patent/SG10201908019UA/en unknown
- 2016-03-03 HR HRP20221142TT patent/HRP20221142T1/en unknown
- 2016-03-03 LT LTEPPCT/US2016/020780T patent/LT3265487T/en unknown
- 2016-03-03 CA CA2978439A patent/CA2978439A1/en active Pending
- 2016-03-03 ES ES16709666T patent/ES2927297T3/en active Active
- 2016-03-03 PL PL16709666.8T patent/PL3265487T3/en unknown
- 2016-03-03 SI SI201631598T patent/SI3265487T1/en unknown
- 2016-03-03 HU HUE16709666A patent/HUE059644T2/en unknown
- 2016-03-03 RS RS20220886A patent/RS63589B1/en unknown
- 2016-03-03 AR ARP160100560A patent/AR103840A1/en unknown
- 2016-03-03 US US15/555,500 patent/US11325970B2/en active Active
-
2017
- 2017-08-31 IL IL254239A patent/IL254239B2/en unknown
-
2022
- 2022-04-11 US US17/717,967 patent/US11834495B2/en active Active
-
2023
- 2023-10-23 US US18/492,150 patent/US20240117028A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201908019UA (en) | MODIFIED-IgG ANTIBODIES THAT BIND TRANSFORMING GROWTH FACTOR-β1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY | |
| PH12020550408A1 (en) | Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies | |
| MX2020009121A (en) | Use of anti-human sirpa v1 antibodies and method for producing anti-sirpa v1 antibodies. | |
| MY190771A (en) | Anti-pd-l1 antibodies and uses thereof | |
| PH12019502785A1 (en) | Anti trbc1 antigen binding domains | |
| NZ602320A (en) | Bispecific, bivalent anti-vegf/anti-ang-2 antibodies | |
| EP4248996A3 (en) | Anti-trem2 antibodies and methods of use thereof | |
| MA39266A (en) | Bispecific antibodies against cd3epsilon and bcma | |
| MX2014004521A (en) | Stable multiple antigen-binding antibody. | |
| MX2016015389A (en) | Antibodies binding to human and cynomolgus cd3 epsilon. | |
| PH12020551173A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| MX2016004928A (en) | Cross-reactive staphylococcus aureus antibody sequences. | |
| EA201791270A1 (en) | MODIFIED APRIL-BINDING ANTIBODIES | |
| AU2012307816A8 (en) | Anti-alphabeta TCR antibody | |
| NZ586357A (en) | Antibodies to the pcrv antigen of pseudomonas aeruginosa | |
| WO2019094595A3 (en) | Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies | |
| NZ594682A (en) | Fully human antibodies specific to cadm1 | |
| EA201691782A1 (en) | ANTIBODIES SPECIFIC TO THE RECEPTOR OF INSULIN-LIKE GROWTH FACTOR 1, AND THEIR APPLICATION | |
| JOP20190246A1 (en) | Monoclonal antibody to pd-l1 | |
| MX2018001596A (en) | Humanized anti-ccr7 receptor antibodies. | |
| MX2022007231A (en) | Anti-mertk antibodies and methods of use thereof. | |
| MX2022007456A (en) | scFv-Fc DIMERS THAT BIND TRANSFORMING GROWTH FACTOR-β1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY. | |
| WO2016127104A3 (en) | Tetra-specific, octameric binding agents and antibodies against clostridium difficile toxin a and toxin b for treatment of c. difficile infection | |
| WO2020023644A3 (en) | Antibody directed against s. aureus clumping factor a (clfa) | |
| NZ594668A (en) | Humanised antibodies with anti-tumour activity |